You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大摩 :先聲藥業(HK.2096)2022年可關注催化劑較多 料有多個IND獲批
格隆匯 01-21 15:43

大摩發研報稱,在2022年,除了對仿製藥風險過高的製藥公司保持謹慎之外,MS將優先考慮有能力進行可持續管線開發的創新公司,例如通過關鍵候選藥物驅動增長,並持續加大研發投入和商業發展的先聲藥業(HK.2096)等公司。先聲藥業在2022年可關注的催化劑較多,例如:先必新和恩維達的銷量快速上漲,潛在的License-in及License-out交易,新冠藥物的IND及臨牀進展,以及其他研發進展(例如TNFR2,先必新舌下片,SERD等),預期將有多個IND將獲批。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account